### PF-0417-2 DIV

## What is claimed is:

1. A pulified polypeptide comprising an amino acid sequence selected from the group consisting of: an amino acid sequence selected from the group consisting of SEQ ID NO:1, a) SEQ ID NO:3, and SEQ ID NO:5, b) a naturally-occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEO ID NO:1, SEQ ID NO:3, and SEQ ID NO:5, 10 c) a biologically-active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5, and an immunogenic fragment of an amino acid sequence selected from the group d) consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5. 2. An isolated polypeptide of claim 1, having a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID\NO:3, and SEQ ID NO:5.

- 3. An isolated polynucleotide encoding a polypeptide of claim 1.
- 4. An isolated polynucleotide encoding a polypeptide of claim 2.
- 5. An isolated polynucleotide of claim 4, having a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6.
- 6. A recombinant polynucleotide comprising a promoter sequence operably linked to 25 a polynucleotide of claim 3.
  - 7. A cell transformed with a recombinant polynucleotide of claim 6.
- 8. A method for producing a polypeptide of claim 1, the method comprising: 30
  - culturing a cell under conditions suitable for expression of the polypeptide, a)

### PF-0417-2 DIV

5

10

- wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
- b) recovering the polypeptide so expressed.
- 9. A method of claim 8, wherein the polypeptide has a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5.
  - 10. An isolated antibody which specifically binds to a polypeptide of claim 1.
- 11. An isolated polynucleotide comprising a sequence selected from the group consisting of:
  - a polynucleotide sequence selected from the group consisting of SEQ ID
    NO:2, SEQ ID NO:4, and SEQ ID NO:6,
  - a naturally-occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6,
  - c) a polynucleotide sequence complementary to a),
  - d) a polynucleotide sequence complementary to b) and
  - e) a ribonucleotide equivalent of a)-d).
- 12. An isolated polynucleotide comprising at least 60 contiguous nucleic acids of claim 11.
- 13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
  - a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is

25

#### PF-0417-2 DIV

5

10

25

formed between said probe and said target polynucleotide or fragments thereof, and

- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
- 14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.
- 15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
  - a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
  - b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

16. A pharmaceutical composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

- 17. A pharmaceutical composition of claim 16, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5.
- 18. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:
  - a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
  - b) detecting agonist activity in the sample.
- 19. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:
- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

5

# PF-0417-2 DIV

- b) detecting antagonist activity in the sample.
- 20. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 4, the method comprising:
  - a) exposing a sample comprising the target polynucleotide to a compound, and
  - b) detecting altered expression of the target polynucleotide.

add a3